Skip to main content
Top
Published in: Journal of Genetic Counseling 6/2013

01-12-2013 | Genetic Counseling: A Global Perspective

Genetic Counseling Services and Training of Genetic Counselors in Israel: An Overview

Authors: Michal Sagi, Wendy R. Uhlmann

Published in: Journal of Genetic Counseling | Issue 6/2013

Login to get access

Abstract

Genetic counseling services have existed in Israel since 1964 and are available in almost all the major hospitals. Given the socialized healthcare system and small country size, genetic services are generally accessible and often free. The existence of founder mutations in various communities in Israel makes genetic testing easier to perform. Yet, the ethnic, cultural and religious diversity of the population has major implications on the design of the screening programs and the use of genetic services. The Israeli Association of Genetic Counselors (IAGC) was established in 2008 and had existed informally since 1989. There are two Master level genetic counseling training programs (6 students/class, 2 year program): Hebrew University-Hadassah Medical School (established in 1997) and the Technion (established in 2009). Genetic counselors’ clinical training is largely observational and 2 years of supervised counseling sessions post degree are required for board exam eligibility. Genetic counselors are licensed and lead counseling sessions individually, but currently must work under medical geneticist supervision. This is the first article to summarize the history and training of Master level genetic counselors in Israel. Genetic services, coverage and regulations are also described.
Literature
go back to reference Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., et al. (1997). The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics, 60, 505–514.PubMed Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., et al. (1997). The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics, 60, 505–514.PubMed
go back to reference Bach, G., Zeigler, M., & Zlotogora, J. (2007). Prevention of lysosomal storage disorders in Israel. Molecular Genetics and Metabolism, 90, 353–357.PubMedCrossRef Bach, G., Zeigler, M., & Zlotogora, J. (2007). Prevention of lysosomal storage disorders in Israel. Molecular Genetics and Metabolism, 90, 353–357.PubMedCrossRef
go back to reference Balkite, E. A., & Smith, M. E. (1999). Evolving roles, expanding opportunities. In W. R. Uhlmann, J. R. Schuette, & B. M. Yashar (Eds.), A guide to genetic counseling (2nd ed., pp. 523–551). New York: Wiley-Blackwell. Balkite, E. A., & Smith, M. E. (1999). Evolving roles, expanding opportunities. In W. R. Uhlmann, J. R. Schuette, & B. M. Yashar (Eds.), A guide to genetic counseling (2nd ed., pp. 523–551). New York: Wiley-Blackwell.
go back to reference Ben-Shachar, S., Orr-Urtreger, A., Bardugo, E., Shomrat, R., & Yaron, Y. (2011). Large-scale population screening for spinal muscular atrophy: clinical implications. Genetics in Medicine, 13, 110–114.PubMedCrossRef Ben-Shachar, S., Orr-Urtreger, A., Bardugo, E., Shomrat, R., & Yaron, Y. (2011). Large-scale population screening for spinal muscular atrophy: clinical implications. Genetics in Medicine, 13, 110–114.PubMedCrossRef
go back to reference Berkenstadt, M., Ries-Levavi, L., Cuckle, H., Peleg, L., & Barkai, G. (2007). Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenatal Diagnosis, 27, 991–994.PubMedCrossRef Berkenstadt, M., Ries-Levavi, L., Cuckle, H., Peleg, L., & Barkai, G. (2007). Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenatal Diagnosis, 27, 991–994.PubMedCrossRef
go back to reference Chemke, J., & Zlotogora, J. (1997). Genetic services in Israel. European Journal of Human Genetics, 5(suppl2), 105–111.PubMed Chemke, J., & Zlotogora, J. (1997). Genetic services in Israel. European Journal of Human Genetics, 5(suppl2), 105–111.PubMed
go back to reference Cohen, T., Vardi-Saliternik, R., & Friedlander, Y. (2004). Consanguinity, intracommunity and intercommunity marriages in a population sample of Israeli Jews. Annals of Human Biology, 31, 38–48.PubMedCrossRef Cohen, T., Vardi-Saliternik, R., & Friedlander, Y. (2004). Consanguinity, intracommunity and intercommunity marriages in a population sample of Israeli Jews. Annals of Human Biology, 31, 38–48.PubMedCrossRef
go back to reference Goldberg, Y., Porat, R. M., Kedar, I., Shochat, C., Sagi, M., Eilat, A., et al. (2008). Mutation spectrum in HNPCC in the Israeli population. Familial Cancer, 7, 309–317.PubMedCrossRef Goldberg, Y., Porat, R. M., Kedar, I., Shochat, C., Sagi, M., Eilat, A., et al. (2008). Mutation spectrum in HNPCC in the Israeli population. Familial Cancer, 7, 309–317.PubMedCrossRef
go back to reference Jaber, L., Halpern, G. J., & Shohat, T. (2000). Trends in the frequencies of consanguineous marriages in the Israeli Arab community. Clinical Genetics, 58, 106–110.PubMedCrossRef Jaber, L., Halpern, G. J., & Shohat, T. (2000). Trends in the frequencies of consanguineous marriages in the Israeli Arab community. Clinical Genetics, 58, 106–110.PubMedCrossRef
go back to reference Levy-Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., et al. (1997). Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics, 60, 1059–1067.PubMed Levy-Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., et al. (1997). Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics, 60, 1059–1067.PubMed
go back to reference Rosner, G., Rosner, S., & Orr-Urteger, A. (2009). Genetic testing in Israel: an overview. Annual Review of Genomics and Human Genetics, 10, 175–92.PubMedCrossRef Rosner, G., Rosner, S., & Orr-Urteger, A. (2009). Genetic testing in Israel: an overview. Annual Review of Genomics and Human Genetics, 10, 175–92.PubMedCrossRef
go back to reference Sagi, M. (1998). Ethical aspects of genetic screening in Israel. Science in Context, 11, 419–429.PubMedCrossRef Sagi, M. (1998). Ethical aspects of genetic screening in Israel. Science in Context, 11, 419–429.PubMedCrossRef
go back to reference Sagi, M., Eilat, A., Ben Avi, L., Goldberg, Y., Bercovich, D., Hamburger, T., et al. (2011). Two BRCA1/2 founder mutations in Jews of Sephardic origin. Familial Cancer, 10, 59–63.PubMedCrossRef Sagi, M., Eilat, A., Ben Avi, L., Goldberg, Y., Bercovich, D., Hamburger, T., et al. (2011). Two BRCA1/2 founder mutations in Jews of Sephardic origin. Familial Cancer, 10, 59–63.PubMedCrossRef
go back to reference Sher, C., Romano-Zelekha, O., Green, M., & Shohat, T. (2003). Factors affecting performance of prenatal genetic testing by Israeli Jewish women. American Journal of Medical Genetics, 120A, 418–422.PubMedCrossRef Sher, C., Romano-Zelekha, O., Green, M., & Shohat, T. (2003). Factors affecting performance of prenatal genetic testing by Israeli Jewish women. American Journal of Medical Genetics, 120A, 418–422.PubMedCrossRef
go back to reference Shiri-Sverdlov, R., Gershoni-Baruch, R., Ichezkel-Hirsch, G., Gotlieb, W. H., Bruchim Bar-Sade, R., Chetrit, A., et al. (2001). The Tyr978X BRCA1 mutation in Non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Community Genetics, 4, 50–55.PubMedCrossRef Shiri-Sverdlov, R., Gershoni-Baruch, R., Ichezkel-Hirsch, G., Gotlieb, W. H., Bruchim Bar-Sade, R., Chetrit, A., et al. (2001). The Tyr978X BRCA1 mutation in Non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Community Genetics, 4, 50–55.PubMedCrossRef
go back to reference Walker, A. P. (1999). The practice of genetic counseling. In W. R. Uhlmann, J. R. Schuette, & B. M. Yashar (Eds.), A guide to genetic counseling (2nd ed., pp. 1–32). New York: Wiley-Blackwell. Walker, A. P. (1999). The practice of genetic counseling. In W. R. Uhlmann, J. R. Schuette, & B. M. Yashar (Eds.), A guide to genetic counseling (2nd ed., pp. 1–32). New York: Wiley-Blackwell.
go back to reference Zlotogora, J., & Chemke, J. (1995). Medical genetics in Israel. European Journal of Human Genetics, 3, 147–154.PubMed Zlotogora, J., & Chemke, J. (1995). Medical genetics in Israel. European Journal of Human Genetics, 3, 147–154.PubMed
go back to reference Zlotogora, J., Haklai, Z., & Leventhal, A. (2007a). Utilization of prenatal diagnosis and termination of pregnancies for the prevention of Down syndrome in Israel. The Israel Medical Association Journal, 9, 600–602. Zlotogora, J., Haklai, Z., & Leventhal, A. (2007a). Utilization of prenatal diagnosis and termination of pregnancies for the prevention of Down syndrome in Israel. The Israel Medical Association Journal, 9, 600–602.
go back to reference Zlotogora, J., van Baal, S., & Patrinos, G. P. (2007b). Documentation of inherited disorders and mutation frequencies in the different religious communities in Israel in the Israeli National Genetic Database. Human Mutation, 28, 944–949.CrossRef Zlotogora, J., van Baal, S., & Patrinos, G. P. (2007b). Documentation of inherited disorders and mutation frequencies in the different religious communities in Israel in the Israeli National Genetic Database. Human Mutation, 28, 944–949.CrossRef
go back to reference Zlotogora, J., Carmi, R., Lev, B., & Shalev, S. A. (2009a). A targeted population carrier screening program for severe and frequent genetic diseases in Israel. European Journal of Human Genetics, 17, 591–597.CrossRef Zlotogora, J., Carmi, R., Lev, B., & Shalev, S. A. (2009a). A targeted population carrier screening program for severe and frequent genetic diseases in Israel. European Journal of Human Genetics, 17, 591–597.CrossRef
go back to reference Zlotogora, J., van Baal, S., & Patrinos, G. P. (2009b). The Israeli national genetic database. IMAJ, 11, 373–375. Zlotogora, J., van Baal, S., & Patrinos, G. P. (2009b). The Israeli national genetic database. IMAJ, 11, 373–375.
go back to reference Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., et al. (2007). Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA: The Journal of the American Medical Association, 298, 1281–1290. Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., et al. (2007). Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA: The Journal of the American Medical Association, 298, 1281–1290.
Metadata
Title
Genetic Counseling Services and Training of Genetic Counselors in Israel: An Overview
Authors
Michal Sagi
Wendy R. Uhlmann
Publication date
01-12-2013
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 6/2013
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-013-9576-4

Other articles of this Issue 6/2013

Journal of Genetic Counseling 6/2013 Go to the issue

Genetic Counseling: A Global Perspective

French Professionals in Genetic Counselor Careers

Genetic Counseling: A Global Perspective

An Overview of Genetic Counseling in Cuba

Genetic Counseling: A Global Perspective

Iceland—Genetic Counseling Services